FDA approves Synribo for chronic myelogenous leukemia
The U.S. Food and Drug Administration today approved Synribo to treat adults with CML. Synribo is intended to be used in patients whose cancer progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors, also used to treat CML. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.